Amsterdam Molecular Therapeutics' (AMT) shares have been delisted from NYSE Euronext in Amsterdam, with 16th November being the last trading date. As of 19th November, AMT's liquidation is finalised and the legal entity, AMT, ceased to exist. As a consequence of AMT ceasing to exist, all AMT shares also ceased to exist on 19th November, without any (further) distribution or compensation to their holders. AMT shareholders that hold their AMT shares in book entry form will have had their position in AMT shares in their securities account struck and deleted as per 19th November.
On 30th March, an extraordinary general meeting of shareholders approved a major corporate restructuring and financing transaction involving the disposal of the Group's entire business and operations to uniQure and the subsequent dissolution, liquidation and delisting of AMT.